SEC Tracker
Get the app
VYGR · XBRL financial data

Voyager Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (VYGR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers4,61490,061*19,51629,57824,6296,278*6,4735,20013,36515,336*2,5933,165
Research and development25,86325,756*27,09234,45230,24135,583*31,52631,33035,86635,952*24,60222,041
General and administrative8,25810,242*8,60710,1518,1688,994*9,64010,4958,0939,316*8,2617,516
Total operating expenses34,12135,998*35,69944,60338,40944,577*41,16641,82543,95945,268*32,86329,557
Operating income (loss)(29,507)54,063*(16,183)(15,025)(13,780)(38,299)*(34,693)(36,625)(30,594)(29,932)*(30,270)(26,392)
Other income (expense)0*0*—20200402*418427400404*435411
Income tax expense (benefit)(177)822*142443584*3715839*1420
Net income (loss)(25,901)56,395*(11,330)(10,141)(9,044)(34,487)*(31,021)(33,382)(27,892)(27,426)*(27,937)(24,473)
Earnings per share, basic USD per share(0.59)1.28*(0.20)(0.18)(0.16)(0.59)*(0.53)(0.57)(0.47)(0.47)*(0.47)(0.40)
Earnings per share, diluted USD per share(0.59)1.16*(0.20)(0.18)(0.16)(0.59)*(0.53)(0.57)(0.47)(0.47)*(0.47)(0.40)
Weighted average shares, basic thousands of shares43,86544,019*57,11757,72257,85157,975*58,35058,66658,80358,938*59,49660,548
Weighted average shares, diluted thousands of shares43,86548,667*57,11757,72257,85157,975*58,35058,66658,80358,938*59,49660,548

Balance sheet

CSV

Fiscal quarters (VYGR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents65,26968,802143,07876,127112,52571,36774,75543,94045,12565,30043,31435,769
Marketable securities187,667162,073256,490294,894232,835195,317161,264171,653163,805131,14798,16580,569
Marketable securities, non-current——980——65,70459,10346,44620,0815,24430,18132,476
Prepaid and other current assets5,7365,3186,1127,2988,4157,9457,0779,7716,6184,3283,8575,736
Total current assets261,925319,684409,137381,570373,443276,809245,206227,889219,585202,687146,981125,228
Property and equipment, net17,10916,49417,38116,26715,20114,31413,92913,91913,29113,13612,21811,194
Right-of-use asset14,02613,51039,20435,51434,52333,34932,12830,97329,74028,47827,20925,905
Total assets294,653351,281469,592436,225426,041393,050353,240322,101288,311252,281219,325197,753
Accounts payable3,2701,6047,5792,6053,1603,9962,6341,8042,1165,0132,7231,614
Accrued liabilities11,05116,8237,59510,27311,44214,1719,05312,02514,95312,0986,9727,951
Total current liabilities61,68864,50872,55340,13044,21049,78840,21241,98335,49526,54117,45316,685
Lease liability, non-current17,91917,09341,99540,20538,36836,49934,56632,56730,52028,65927,20325,691
Total liabilities118,433114,961128,706100,80895,73193,29080,53878,15768,48656,20045,65643,376
Accumulated deficit(317,577)(261,182)(272,512)(282,653)(291,697)(326,184)(357,205)(390,587)(418,479)(445,905)(473,842)(498,315)
Total stockholders' equity176,220236,320340,886335,417330,310299,760272,702243,944219,825196,081173,669154,377
Total liabilities and equity294,653351,281469,592436,225426,041393,050353,240322,101288,311252,281219,325197,753
Common shares outstanding (cover page) thousands of shares43,99554,30154,39454,53354,62655,20755,33655,46955,60059,59960,42161,618

Cash flows

CSV

Fiscal quarters (VYGR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(25,901)56,395*(11,330)(10,141)(9,044)(34,487)*(31,021)(33,382)(27,892)(27,426)*(27,937)(24,473)
Stock-based compensation2,878*3,045*3,5734,042*3,433*3,737*3,6734,133*3,460*3,521*2,4882,433*
Net cash from operating activities(21,051)*(23,760)*58,767(31,580)*(27,968)*(14,529)*(37,895)(33,261)*(31,048)*(30,263)*(33,419)(25,842)*
Purchases of property and equipment782*755*2,141967*258*155*6581,105*207*626*140*
Net cash from investing activities(158,304)*26,833*(96,065)(35,943)*64,352*(27,203)*41,2011,933*34,888*47,424*8,10115,391*
Proceeds from issuing common stock——93,4730*0*0*————3,0382,630*
Net cash from financing activities331*460*112,856571*14*574*82513*85*136*3,3322,906*
Net change in cash(179,024)*3,533*75,558(66,952)*36,398*(41,158)*3,388(30,815)*3,925*17,297*(21,986)(7,545)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Voyager Therapeutics35,7693,165(25,842)*61.6M4.5 quarters 10-QJun 30, 2026
Eledon Pharmaceuticals6,803not reported(22,677)*81.3M3.9 quarters 10-QJun 30, 2026
Puma Biotechnology36,53756,5021,624*51.6M— 10-QJun 30, 2026
Neurogene112,485not reported(23,761)*20.0M9.5 quarters 10-QJun 30, 2026
Aclaris Therapeutics19,1671,629(19,847)*147.2M4.6 quarters 10-QJun 30, 2026
Alpha Cognition41,3846,093(6,859)*21.8M6.0 quarters 10-QJun 30, 2026
Vistagen Therapeutics16,991not reported(14,707)44.4M2.2 quarters 10-QJun 30, 2026
Sangamo Therapeutics27,5861,442(19,282)414.3M1.4 quarters 10-QMar 31, 2026
Agenus18,73834,518(31,199)*45.0M0.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.